Neoadjuvant chemoradiation regimens for oesophageal cancer vary widely. Besides traditional outcome variables (such as survival), other parameters should be analysed (for example toxicity) to assess whether the risks of chemoradiation are sufficiently compensated for by the benefits.

No abstract

No abstract

Patients who survive 1 year or more after potentially curative treatment for esophageal cancer can lead satisfactory lives. The results of this study can be used when informing patients with esophageal cancer about the long-term effects of treatment.

Background

Outcome of low-volume esophageal surgery can be comparable to published high-surgical-volume results. More relevant factors other than hospital volume alone should be taken into account to improve outcome of esophageal cancer surgery.

With individual treatment planning, different regimens of chemoradiation for esophageal cancer resulted in acceptable rates of toxicity and efficacy.

No abstract